All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Smartphone Apps

October 2nd 2012

There now are many phone-based "self-help" tools.

FDA Approves Regorafenib for Advanced Colorectal Cancer

September 27th 2012

The FDA has approved regorafenib, an oral multikinase inhibitor, to treat patients with metastatic colorectal cancer whose disease has progressed after prior therapy.

Updated BOLERO-2 Data Support Efficacy of Everolimus in Breast Cancer

September 20th 2012

Updated results from the BOLERO-2 trial support the study's earlier findings that mTOR kinase inhibitor everolimus improves survival for postmenopausal patients with breast cancer.

Immunotherapy: Personalized Treatment for Advanced Prostate Cancer

September 19th 2012

In April 2010, the FDA approved sipuleucel-T for patients with castration-resistant and metastatic prostate cancer, providing a new treatment that would help the body fight its own cancer.

Final Results of Abiraterone Acetate in Advanced Prostate Cancer Show Significantly Improved Survival

September 18th 2012

Abiraterone acetate significantly improved overall survival with positive responses seen in several subgroups of patients with metastatic castration-resistant prostate cancer.

TH-302 Shows Non-Significant Improvement in OS for Advanced Pancreatic Cancer

September 17th 2012

A secondary analysis of a combination of an investigational hypoxia-targeted agent called TH-302 with gemcitabine slightly improved overall survival, but the results were not statistically significant.

Cancer Occurrence Among 9/11 First Responders

September 17th 2012

The World Trade Center Health Program will begin covering 50 cancer types.

Study Supports Role for ALND in Early Breast Cancer

September 14th 2012

Patients with early-stage breast cancer at high risk of residual nodal disease might benefit from axillary lymph node dissection.

Medication Errors

September 11th 2012

Use of interception practices was associated with fewer medication errors.

Alimta Combination Fails Survival Objectives in Phase III Study

September 6th 2012

Eli Lilly announced that a combination regimen of their chemotherapy drug Alimta and Avastin failed to improve survival in late stage non-squamous non-small cell lung cancer.

Bosutinib Approved for Previously Treated CML

September 4th 2012

The FDA has approved bosutinib for the treatment of patients with Philadelphia chromosome-positive chronic myelogenous leukemia who are intolerant or who have become resistant to prior therapy.

Daily Aspirin and Cancer Mortality

September 4th 2012

Recent analysis finds that mortality is reduced, but the association is smaller than previously reported.

Enzalutamide Approved for Late-Stage Prostate Cancer

August 31st 2012

The FDA approved enzalutamide for use in patients with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel and hormonal therapy.

FDA Grants Priority Review to New Indication for Abiraterone Acetate

August 29th 2012

The FDA announced that Priority Review has been granted to abiraterone acetate for certain advanced prostate cancer cases based on positive data presented at the ASCO annual meeting.

FDA Approval Sought for T-DM1

August 27th 2012

Genentech is seeking the FDA's approval to offer T-DM1 for patients with HER2-positive metastatic breast cancer amid updated results from the pivotal EMILIA trial showing significantly improved OS.

Researchers Determine Immune Parameters that Lead to Better Survival in Patients who Receive Sipuleucel-T

August 17th 2012

Researchers have determined that patients who received sipuleucel-T (Provenge, Dendreon) developed immune parameters that correlate to improved overall survival, giving researchers a better understanding of how the immunotherapy works at a cellular level to improve survival.

Newly Published Results Show Survival Benefit with Enzalutamide in Prostate Cancer

August 16th 2012

The novel drug enzalutamide (formerly MDV3100) significantly improved overall survival in men with metastatic castrate-resistant prostate cancer (mCRPC).

Myriad Genetics Maintains BRCA1 and BRCA2 Patents, Appellate Court Rules

August 16th 2012

On August 16, the US Federal Circuit Court of Appeals ruled 2-1 to uphold its original decision that Myriad Genetics has the right to hold the patent to the BRCA1 and BRCA2 genes.

Hospital-Acquired Infection

August 14th 2012

More patients assigned per nurse and higher nurse burnout rates contribute to higher infection rates.

FDA Approves Marqibo for Rare Form of Leukemia

August 9th 2012

The FDA approved Marqibo to treat patients with Philadelphia chromosome-negative adult acute lymphoblastic leukemia following at least two relapses or failed treatment.